Question 1

What is Olaparib?

Accepted Answer

Olaparib belongs to a class of drugs known as poly (ADP-ribose) polymerase (PARP) inhibitors. These medications work by blocking a specific enzyme that helps cells repair damaged DNA.

By preventing this repair process, the drug causes DNA damage to accumulate within cancer cells, which eventually leads to their death. This mechanism specifically targets cells that already have difficulty repairing DNA, helping to slow or stop the growth of the tumor.

Question 2

What is Olaparib used for?

Accepted Answer

Olaparib is used to treat:

ovarian cancer

fallopian tube cancer

primary peritoneal cancer

and others

Question 3

How does Olaparib work?

Accepted Answer

Mechanism of Action

Olaparib belongs to a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. PARP is a natural enzyme found in cells that helps repair damaged DNA. In healthy cells, this repair process is essential for survival.

Cancer cells also use PARP to fix DNA damage. When olaparib blocks the PARP enzyme, it prevents the cancer cells from repairing certain types of DNA breaks. This leads to an accumulation of genetic damage within the cell.

Targeting Specific Mutations

Olaparib is particularly effective against cancer cells that have specific genetic mutations, such as BRCA1 or BRCA2. These mutations already limit the cell's ability to repair DNA through other pathways. By blocking the PARP pathway as well, olaparib leaves the cancer cell with no way to fix its DNA, eventually causing the cell to die.

This process helps to:

Slow the growth of the tumor.

Shrink existing tumors.

Delay the progression of the disease.

Question 4

What are the brand names for Olaparib?

Accepted Answer

Olaparib is sold under the brand name Lynparza .

Question 5

What are the active ingredients in Olaparib?

Accepted Answer

The active ingredient in Olaparib is olaparib .

Question 6

What are the side effects of Olaparib?

Accepted Answer

Common side effects of Olaparib may include:

Nausea

Fatigue

Vomiting

and others.

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Olaparib?

Accepted Answer

Olaparib belongs to the PARP inhibitor drug class.

Question 8

What is the dosage of Olaparib and how do I take it?

Accepted Answer

How to Take Olaparib

Olaparib is taken by mouth, usually twice every day. It is important to take the doses at approximately the same time each day, roughly 12 hours apart. This medication can be taken with or without a meal.

Swallow the medication whole. Do not crush, chew, break, or dissolve the tablets or capsules. If you have trouble swallowing the medication, speak with your healthcare provider for guidance.

Important Considerations

Formulations: Olaparib is available in different forms, such as tablets and capsules. These forms are not interchangeable and cannot be swapped for one another. Always use the specific form and strength prescribed by your doctor.

Dietary Restrictions: Avoid consuming grapefruit, grapefruit juice, or Seville oranges while being treated with this medication. These products can increase the levels of the drug in your blood and may increase the risk of side effects.

Missed Dose

If you miss a dose of olaparib, skip the missed dose and take your next dose at the regularly scheduled time. Do not take an extra dose or double the dose to make up for the one you missed.

Question 9

Is Olaparib safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Olaparib may cause serious harm to a developing fetus. Healthcare providers typically require a pregnancy test before starting this medication to ensure the patient is not pregnant. It is important to discuss reproductive health and potential risks with a doctor before beginning treatment.

Effective contraception is necessary for both men and women during and after treatment:

Females: Use effective birth control during treatment and for at least 6 months after the final dose.

Males: Use effective contraception, such as condoms, during treatment and for at least 3 months after the final dose if a partner is pregnant or could become pregnant. Males should also avoid donating sperm during this time.

Breastfeeding

It is currently unknown whether olaparib passes into human breast milk. Because of the risk of serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment and for at least 1 month after the last dose. Patients should talk to their healthcare provider about the safest way to feed their infant while taking this medication.

Question 10

What forms and strengths does Olaparib come in?

Accepted Answer

Olaparib is supplied for oral administration in the following forms:

Tablets

Capsules

It is important to note that olaparib tablets and capsules are not interchangeable. These two forms have different bioavailability and are not substituted for one another on a direct basis. Patients should only use the specific form prescribed by their healthcare provider and should not switch between tablets and capsules unless specifically instructed to do so.

Question 11

What is the FDA approval status of Olaparib?

Accepted Answer

FDA Approval and Indications

Olaparib was first approved by the FDA as a PARP inhibitor. It is currently approved for the treatment of several specific types of cancer, often depending on the presence of certain genetic biomarkers such as BRCA mutations.

Approved indications include:

Ovarian Cancer: Used for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. It is also approved for first-line maintenance in BRCA-mutated advanced ovarian cancer.

Breast Cancer: Approved for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously received chemotherapy.

Prostate Cancer: Approved for certain patients with metastatic castration-resistant prostate cancer (mCRPC), including those with HRR gene mutations or in combination with abiraterone for BRCA-mutated cases.

Pancreatic Cancer: Used as a maintenance treatment for patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

Biomarker Testing

The FDA labeling for olaparib includes information regarding pharmacogenomic biomarkers. Treatment eligibility is often determined by FDA-approved companion diagnostic tests that identify BRCA1, BRCA2, or other homologous recombination repair (HRR) gene mutations.

Regulatory Requirements

Olaparib is a prescription-only medication. While it does not currently have a Boxed Warning, the FDA requires monitoring for serious potential risks such as myelodysplastic syndrome or acute myeloid leukemia, which have been reported in clinical trials.

Question 12

What should I know about Olaparib and breast cancer?

Accepted Answer

Indications for Breast Cancer

Olaparib is used to treat adults with a specific type of inherited (germline) BRCA-mutated, HER2-negative metastatic breast cancer. It is typically prescribed for patients who have already received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. If the cancer is hormone receptor (HR)-positive, patients should have also received endocrine therapy or be considered inappropriate candidates for it.

Additionally, olaparib is approved as an adjuvant treatment for patients with germline BRCA-mutated, HER2-negative high-risk early breast cancer who have previously been treated with chemotherapy before or after surgery.

Mechanism of Action

As a PARP inhibitor, olaparib blocks an enzyme called poly (ADP-ribose) polymerase (PARP) that helps repair DNA. Because BRCA-mutated cancer cells already have a limited ability to repair DNA, blocking the PARP enzyme causes DNA damage to accumulate to a point where the cancer cells can no longer survive.

Required Testing

Treatment with olaparib requires confirmation of a germline BRCA mutation. Healthcare providers use specific FDA-approved companion diagnostic tests to determine if a patient's genetic profile makes them a candidate for this therapy.

Olaparib

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Breast Cancer Information

FAQ

Found an Error?